 Leap Therapeutics Inc NASDAQ: LPTX announced updated data from the first-line cohort of the DisTinGuish Phase 2a trial evaluating DKN-01 combined with BeiGene Ltds NASDAQ: BGNE tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer GGEJ. The data were presented at the European Society for Medical Oncology ESMO21 Congress. 